Publications database

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

The EMCDDA 2008 work programme is the second annual work plan to implement the objectives identified in the broader 2007–2009 strategy and work programme, and provides the operational details of the activities...

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

The report on the state of the drugs problem in Europe presents the EMCDDA's yearly overview of the drug phenomenon. This is an essential reference book for policymakers, specialists and practitioners in...

In a Selected issue on ‘Cocaine and crack cocaine: a growing public health issue’ the EMCDDA shows that, in some European countries, there has been a marked increase in recent years in...

Cocaine use presents new challenges for Europe’s drug treatment services. Although services can leverage experiences gained in responding to other types of drug problems, the pharmacology of cocaine, the social diversity of...

Evidence suggests that early experimentation with psychoactive substances, including alcohol and tobacco, is associated with an increased risk of developing drug problems later in life. In a Selected issue on ‘Drug use...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

Since the late 1990s, much European and world research has addressed the issue of driving under the influence of psychoactive substances. This Selected issue on ‘Drugs and driving’ focuses on driving after...

These practical guidelines have been published to assist the implementation of the Council decision on information exchange, risk-assessment and control of new psychoactive substances. They deal with phase 1 of the measures...